Drug Profile

Vimirogant - AbbVie/Vitae Pharmaceuticals

Alternative Names: AGN-242428; VTP43742

Latest Information Update: 12 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vitae Pharmaceuticals
Developer AbbVie; Allergan
Class Antipsoriatics; Pyridines; Pyrroles; Small molecules
Mechanism of Action Immunosuppressants; Nuclear receptor subfamily 1 group F member 3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Dry eyes
Discontinued Autoimmune disorders; Multiple sclerosis; Plaque psoriasis; Psoriasis

Most Recent Events

18 Mar 2022 Allergan completes a phase II trial in Dry eyes in USA (Topical) (NCT04030962)
08 May 2020 Allergan has been acquired and merged into AbbVie
04 Mar 2020 Phase-II clinical trials in Dry eyes in USA (Topical) in March 2020 (NCT04030962)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com